Evidence map›Paper›PMID 42620997›Full record

ReviewFrontiers in oncology2026

AI-integrated single-cell multi-omics decodes the hepatocellular carcinoma metabolism-immune axis: a new strategy for precision therapeutic targeting.

Zihao Xu, Yifan Liu, Liangbin Cheng, Jun Xu

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zihao XuSchool of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Yifan LiuSchool of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Liangbin ChengDepartment of Hepatology, Hubei Provincial Hospital of Traditional Chinese Medicine Affiliated to Hubei University of Chinese Medicine, Wuhan, Hubei, China.
Jun XuSchool of Basic Medical Sciences, Hubei University of Chinese Medicine, Wuhan, Hubei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune checkpoint inhibitors have improved outcomes for hepatocellular carcinoma, yet most patients do not respond because the tumor's metabolic environment suppresses immune cells. Single-cell RNA sequencing has revealed extensive immune diversity, but conventional analyses cannot link cell states to their physical location or to the metabolic signals that drive dysfunction. Methods: In this review, we examine how artificial intelligence, combined with single-cell and spatial multi-omics, can decode the metabolism-immunity network in liver cancer. We highlight two key metabolic switches: lipid uptake through a scavenger receptor that triggers ferroptosis in killer T cells, and lactate-induced changes in gene regulation that lock macrophages into a tumor-promoting state. We also summarize advanced computational tools including deep learning for data integration, spatial deconvolution, and foundation models that can infer metabolic activity from single-cell data and reconstruct cell movement over time. Results: These approaches enable researchers to identify key metabolic drivers of immune evasion and predict which checkpoints are most actionable. Conclusions: Artificial-intelligence-driven multi-omics transforms hepatocellular carcinoma research from descriptive catalogues into predictive, mechanism-based models, offering a roadmap for designing next-generation immunotherapies.

Indexed as

artificial intelligencehepatocellular carcinomaimmune checkpoint inhibitormetabolic checkpointsingle-cell multi-omicstumor microenvironment

Identifiers

PMID42620997
PMCPMC13487533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.